Bivalirudin versus heparin as an antithrombotic agent in patients treated with a sirolimus-eluting stent

Seung Woon Rha, Pramod K. Kuchulakanti, Rajbabu Pakala, Edouard Cheneau, Jana A. Fournadjiev, Ellen Pinnow, Afework GebreEyesus, George Aggrey, Zuyue Wang, Augusto D. Pichard, Lowell F. Satler, Kenneth M. Kent, Joseph Lindsay, Ron Waksman

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Bivalirudin (Angiomax) is increasingly used as a substitute for heparin in a variety of percutaneous coronary interventions. This retrospective, observational study aimed to evaluate the efficacy and safety of bivalirudin compared with heparin as an antithrombotic regimen in patients treated with sirolimus-eluting stents (Cypher) and found that bivalirudin is clinically safe and feasible, with fewer vascular and ischemic complications compared with heparin.

Original languageEnglish
Pages (from-to)1047-1050
Number of pages4
JournalAmerican Journal of Cardiology
Volume94
Issue number8
DOIs
Publication statusPublished - 2004 Oct 15

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Bivalirudin versus heparin as an antithrombotic agent in patients treated with a sirolimus-eluting stent'. Together they form a unique fingerprint.

  • Cite this

    Rha, S. W., Kuchulakanti, P. K., Pakala, R., Cheneau, E., Fournadjiev, J. A., Pinnow, E., GebreEyesus, A., Aggrey, G., Wang, Z., Pichard, A. D., Satler, L. F., Kent, K. M., Lindsay, J., & Waksman, R. (2004). Bivalirudin versus heparin as an antithrombotic agent in patients treated with a sirolimus-eluting stent. American Journal of Cardiology, 94(8), 1047-1050. https://doi.org/10.1016/j.amjcard.2004.06.065